Join the Only Industry-led Forum Focused on Transcription Factor Therapeutics
With 3 days of tailored content, the inaugural Transcription Factor-Directed Therapies Summit is the only industry-led, face-to-face meeting to dive deep into the progress of TF-directed medicines in precision oncology tactics.
Despite the recent success in transcription factor therapies, the undruggable nature of the target molecules, the complexity of the systems that TFs act in and the challenge of balancing chemistry and biology rationale has resulted in slow development within this space.
From better understanding the role of Factors like P53, STAT3, HIPPO and how best to target them to devising effective clinical strategies, and identifying new biomarkers that can accelerate your candidates to the clinic, this summit will unpack the major obstacles to TF treatment development.
Harness next-generation high throughput screening technologies to identify novel TF targets with University of Bath and St Jude’s Children’s Hospital
Understand how HIPPO plays a role in cancer and how it can be targeted with Ikena Oncology
Explore the link between biological rationale behind the Transcription Network and therapeutic opportunity with Kronos Bio
Discuss the application of novel protein degraders and molecular glues with Pin Therapeutics and Dana Farber
This is your one-of-a-kind chance to accelerate the safe development of Transcription Factor treatments with maximal clinical effect in such a fast-paced business.